NEW YORK (GenomeWeb News) – Johnson & Johnson’s drug research division has licensed Simcyp’s drug modeling and simulation platform, the UK-based firm said today.
Through the license, Johnson & Johnson Pharmaceutical Research and Development will provide access to Simcyp’s population-based Simulator and pediatric module to its global R&D teams for a period of three years. The Simcyp platform provides modeling and simulation of drug absorption, distribution, metabolism, and elimination in virtual populations.
The Sheffield-based company said its platform allows researchers to identify individuals who are at extreme risk for adverse drug reactions, and allows for the minimization of drug exposure to human and animal volunteers. The platform also can help assess and manage potential interactions between drugs before human studies begin, the company said.
Financial terms of the agreement were not released.